|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Behavioral syndromes in Alzheimer's disease:Description and correlates显示文摘 | Frisoni GB Rozzini L Gozzetti A | 1999 | Dement Geriatr Cogn Disord1999，10，： | 1 |
| 2 | Behavioral syndromes in Alzheimer's disease:description and correlates显示文摘 | Frisoni GB Rozzini L Gozzetti A | 1999 | Dement Geriatr Cogn Dicord1999，10，2： | 1 |
| 3 | Weekly bortezomib, pegylated liposomal doxornbicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple mye- loma显示文摘 | Gozzetti A Fabbri A O/iva S | 2010 | Clinical Lymphoma Myeloma and Leukemia2010，10，1： | 1 |
| 4 | Weekly bortezomib, pegylated li- posomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory muhiple myeloma 显示文摘 | Gozzetti A Fabbri A Oliva S | 2010 | Clin Lymphoma Myeloma Leuk2010，10，1： | 1 |
| 5 | Surgical experience with 168 primary liver cell carcinomas treated with hepatic resection显示文摘 | Gozzetti G Mazziotti A Grazi GL | 1993 | J Surg Oncol Suppl1993，3，1： | 1 |
| 6 | Liver resection without blood transfusion显示文摘 | GOZZETTI G MAZZIOTI A GRAZI G L | 1995 | Br J Surg1995，82，8： | 1 |
| 7 | Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia显示文摘 | Fabbri A Gozzetti A Lazzi S | 2006 | Clin Lymphoma Myeloma2006，6，6： | 1 |
| 8 | Fluorescence in situ hybridization uses and limitation显示文摘 | Gozzetti A LeBeau MM | 2000 | Seminars in Hematology2000，37，4： | 1 |
| 9 | A novel t (6;7) (p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission aider therapy with imatinib mesylate显示文摘 | Gozzetti A Tozzuoli D Crupi R | 2004 | Cancer Genet Cytogenet2004，148，2： | 1 |
| 10 | Efficacy of bortezomib,lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia显示文摘 | Gozzetti A Musto P Defina M | 2012 | Br J Haematol2012，157，4： | 1 |
| 11 | Intracraial involvement in plasmarytomas and multLple myeloma: a pictrial essoy 显示文摘 | Cerase A Tarantion A Gozzetti A | 2008 | Neuroradiology2008，50，8： | 1 |
| 12 | Increased serum lactate dehydrogenase isoenzymes in Ph-negative chronic myeloproliferative diseases : A metabolic adaptation? 显示文摘 | Mazzotta S Guerranti R Gozzetti A | 2006 | Hematology2006，11，4： | 1 |
| 13 | Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay显示文摘 | Cerase A Tarantino A Gozzetti A | 2008 | Neuroradiology2008，50，8： | 1 |
| 14 | Fluorescence in situ hybridization: Uses and limitations显示文摘 | Alessandro Gozzetti Michelle M Le Beau | 2000 | Seminars in Hematology2000，，4： | 1 |
| 15 | Weekly bortezomib,pegylated liposomal doxorubicin, and dex- amethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma 显示文摘 | GOZZETTI A FABBRI A OLIVA S | 2010 | Clin Lymphoma Myeloma Leuk2010，10，： | 1 |
| 16 | Weekly bortezomib,pegylated liposomal doxorubicin,and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma显示文摘 | Gozzetti A Fabbri A Oliva S | 2010 | Clin Lymphoma Myeloma Leuk2010，10，1： | 1 |
| 17 | Chemoimmunotherapy with oral low-dose fludarabine,cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia显示文摘 | Gozzetti A Candi V Fabbri A | 2014 | Leuk Res2014，38，8： | 1 |
| 18 | Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice显示文摘 | Jurczyszyn A Grzasko N Gozzetti A | | Am J Hematol0，91，6： | 1 |
| 19 | Central nervous system multiple myeloma显示文摘 | Gozzetti A Cerase A Bocchia M | 2015 | Clin Lymphoma Myeloma Leuk2015，15，6： | 1 |
| 20 | Drug resistance and minimal residual disease in multiple myeloma显示文摘Great progress has been made in improving survival in multiple myeloma(MM)patients over the last 30 years.New drugs have been introduced and complete responses are frequently seen.However,the majority of MM patients do experience a relapse at a variable time after treatment,and ultimately the disease becomes drug-resistant following therapies.Recently,minimal residual disease(MRD)detection has been introduced in clinical trials utilizing novel therapeutic agents to measure the depth of response.MRD can be considered as a surrogate for both progression-free and overall survival.In this perspective,the persistence of a residual therapy-resistant myeloma plasma cell clone can be associated with inferior survivals.The present review gives an overview of drug resistance in MM,i.e.,mutation ofβ5 subunit of the proteasome;upregulation of pumps of efflux;heat shock protein induction for proteasome inhibitors;downregulation of CRBN expression;deregulation of IRF4 expression;mutation of CRBN,IKZF1,and IKZF3 for immunomodulatory drugs and decreased target expression;complement protein increase;sBCMA increase;and BCMA down expression for monoclonal antibodies.Multicolor flow cytometry,or next-generation flow,and next-generation sequencing are currently the techniques available to measure MRD with sensitivity at 10-5.Sustained MRD negativity is related to prolonged survival,and it is evaluated in all recent clinical trials as a surrogate of drug efficacy. | Alessandro Gozzetti Sara Ciofini Anna Sicuranza Paola Pacelli Donatella Raspadori Emanuele Cencini Dania Tocci Monica Bocchia | 2022 | Cancer Drug Resistance2022，5，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员